Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

NOVO NORDISK A/S (NOVO B)
Mes dernières consult.
Most popular
Report
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets
Latest news on NOVO NORDISK A/S
10/23 NOVO NORDISK A/S : - Share repurchase programme
10/23 NOVO NORDISK A/S : - Semaglutide receives positive 16-0 vote in favour of approv..
10/23 NOVO NORDISK A/S : New medicine for obesity hits Qatar market
10/20 NOVO NORDISK A/S : Addressing Diabetes in Nigeria
10/20 NOVO NORDISK A/S : Anemia Prevalence Promotes Growth Of Hematology Drugs Market
10/19 NOVO NORDISK A/S : Reports from Novo Nordisk Provide New Insights into Anterior ..
10/19 NOVO NORDISK A/S : Emanuel Mini moving up to Team Novo Nordisk pro squad
10/18 NOVO NORDISK A/S : Semaglutide receives positive 16-0 vote in favour of approval..
10/18 NOVO NORDISK A/S : - FDA posts briefing materials prior to Advisory Committee me..
10/17 NOVO NORDISK A/S : Emanuel Mini Moves Up to Team Novo Nordisk Pro Squad for the ..
10/17 NOVO NORDISK A/S : FDA gives Novo Nordisk top grades for its diabetes drug semag..
10/16 NOVO NORDISK A/S : Health and Human Services Department (HHS); Food and Drug Adm..
10/16 NOVO NORDISK : FDA posts briefing materials prior to Advisory Committee meeting ..
10/16 NOVO NORDISK A/S : - Share repurchase programme
10/13 NOVO NORDISK A/S : CEO of Fit4D, David Weingard, Announced as Finalist for the L..
10/12 NOVO NORDISK A/S : and HITLAB Team Up for Fourth Annual Innovators Summit
10/12 NOVO NORDISK A/S : Patent Issued for Dose Mechanism for an Injection Device for ..
10/12 NOVO NORDISK A/S : Data from Novo Nordisk Provide New Insights into Serine Endop..
10/11 NOVO NORDISK A/S : - Share repurchase programme
10/09 NOVO NORDISK A/S : Health and Human Services Department (HHS); Food and Drug Adm..
10/09 NOVO NORDISK A/S : - Share repurchase programme
10/07 AWARENESS EVENT ON OBESITY AND ITS H : Losing 510% of body weight reduces risk ..
10/06 NOVO NORDISK A/S : AS - Share repurchase programme
10/05 NOVO NORDISK A/S : Production of key diabetes cells can be improved
10/05 NOVO NORDISK A/S : Study Data from Novo Nordisk Provide New Insights into Obesit..
10/05 NOVO NORDISK A/S : Working Mother names Novo Nordisk one of its "100 Best Compan..
10/05 NOVO NORDISK A/S : Receives FDA Approval for Fiasp®, a New Fast-Acting Mealtime ..
10/05 NOVO NORDISK A/S : Teams Up with HITLAB to Challenge Innovators to Develop Voice..
10/04 NOVO NORDISK A/S : - Status regarding 's holding of its own shares
10/04 NOVO NORDISK A/S : - CHMP endorses Tresiba label update in the EU new label refl..
10/03 NOVO NORDISK A/S : Striking Blood Sugar Balance is Critical for Canadians Living..
10/02 NOVO NORDISK A/S : Status regarding Novo Nordisk's holding of its own shares (30..
10/02 NOVO NORDISK A/S : - Share repurchase programme
10/02 ZGNX Leaps On Trial Data, NVO Gets It Right The 2nd Time, MNKD On Watch
10/01 NOVO NORDISK A/S : appoints new Egypt GM
09/30 NOVO NORDISK A/S : IDF, Novo Nordisk Launch First-Ever Global Survey on Cardiova..
09/30 NOVO NORDISK A/S : 6,791 Shares in Novo Nordisk A/S Purchased by Columbia Partne..
09/29 NOVO NORDISK A/S : appoints new Egypt GM
09/29 NOVO NORDISK A/S : new fast-acting mealtime insulin Fiasp® approved in the US
09/29 NOVO NORDISK A/S : CHMP endorses Tresiba® label update in the EU - new label ref..
09/28 NOVO NORDISK A/S : Patent Issued for Methods of Optimizing Chromatographic Separ..
09/28 NOVO NORDISK A/S : HITLAB West Coast Symposium Sponsored by Novo Nordisk Announc..
09/28 NOVO NORDISK A/S : Egypt appoints New General Manager
09/28 NOVO NORDISK A/S : Egypt appoints New General Manager
09/28 NOVO NORDISK A/S : New-Generation Basal Insulin Tresiba Approved in China
09/28 NOVO NORDISK A/S : assigns new CEO
09/27 NOVO NORDISK A/S : Biogen Appoints Camille Lee as SVP, Alzheimer's disease Thera..
09/27DJNOVO NORDISK A/S : Diabetes Drug Tresiba Approved in China
09/27 NOVO NORDISK A/S : new-generation basal insulin Tresiba® approved in China
09/26 NOVO NORDISK A/S : Biogen Appoints Camille Lee as SVP, Alzheimers Disease Therap..
09/26 NOVO NORDISK A/S : Extends Commitment to World's First All-Diabetes Professional..
09/26 NOVO NORDISK A/S : Madhuri Gurjar, Novo Nordisk Inc.
09/25 NOVO NORDISK A/S : - Share repurchase programme
09/25 NOVO NORDISK A/S : AS - Share repurchase programme
09/23 NOVO NORDISK A/S : Agrees to Pay $58 Million for Failure to Comply With FDA-Mand..
09/22 NOVO NORDISK A/S : aims for GLP-1 sales growth in China
09/21 INNATE PHARMA SA - FIRST HALF OF 201 : delivering key clinical data and strength..
09/18 NOVO NORDISK A/S : - Share repurchase programme
09/18 NOVO NORDISK A/S : - Tresiba trial shows that people with type 2 diabetes who av..
09/17 NOVO NORDISK A/S : Changing Diabetes Fund set up in China
09/16 NOVO NORDISK A/S : Tresiba Trial Shows That People With Type 2 Diabetes Who Avoi..
09/16 NOVO NORDISK A/S : highlights key hypo data from Tresiba at EASD
09/16 NOVO NORDISK A/S : Changing Diabetes Fund set up in China
09/16 NOVO NORDISK A/S : Indiana reaches Medicaid fraud settlement with pharmaceutical..
09/15 NOVO NORDISK A/S : `s Xultophy beats basal insulin in cutting cardiovascular ris..
09/15 NOVO NORDISK A/S : AS - Share repurchase programme
09/15 NOVO NORDISK A/S : AS - Xultophy reduces cardiovascular risk factors in people w..
09/15 NOVO NORDISK A/S : Tresiba® trial shows that people with type 2 diabetes who avo..
09/14 NOVO NORDISK A/S : The Healthcare Leadership Council - Briefing
09/14 BERG & ANDROPHY : $46.5M Settlement in False Claims Act Case Over Alleged Illega..
09/14 NOVO NORDISK A/S : Insurance whistleblower recoveries from Phillips & Cohen case..
09/14 NOVO NORDISK A/S : A S - Fiasp significantly improved overall blood sugar contro..
09/14 NOVO NORDISK A/S : Xultophy reduces cardiovascular risk factors in people with t..
09/14 NOVO NORDISK A/S : Fiasp Significantly Improved Overall Blood Sugar Control in T..
09/14 NOVO NORDISK A/S : Xultophy Reduces Cardiovascular Risk Factors in People With T..
1  2  3  4  5  6  7  8  9  10Next
Financials ( DKK)
Sales 2017 113 B
EBIT 2017 49 131 M
Net income 2017 38 223 M
Finance 2017 18 527 M
Yield 2017 2,40%
P/E ratio 2017 20,69
P/E ratio 2018 19,29
EV / Sales 2017 5,38x
EV / Sales 2018 5,19x
Capitalization 627 B
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 30
Average target price 299  DKK
Spread / Average Target -6,3%
EPS Revisions
Managers
NameTitle
Lars Fruergaard Jørgensen President & Chief Executive Officer
Göran Albert Ando Chairman
Maziar Mike Doustdar Executive Vice President-International Operations
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S25.13%98 961
JOHNSON & JOHNSON23.60%382 202
NOVARTIS13.97%226 404
PFIZER12.13%216 886
ROCHE HOLDING LTD.0.77%207 116
MERCK AND COMPANY8.51%174 223